Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes-Reference-Cited by-同舟云学术

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

Published:2020-06-09 Issue:9 Volume:38 Page:1811-1819
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:

Author:

van Bommel Erik J.M.,Smits Mark M.,Ruiter Danique,Muskiet Marcel H.A.,Kramer Mark H.H.,Nieuwdorp Max,Touw Daan J.,Heerspink Hiddo J.L.,Joles Jaap A.,van Raalte Daniël H.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference46 articles.

1. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome;van Bommel;Clin J Am Soc Nephrol,2017

2. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial;Inzucchi;Diabetes Care,2018

3. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019

4. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019

5. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis;Fox;Lancet,2012

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reliability of heart rate in reflecting cardiac sympathetic overdrive in type 2 diabetes mellitus;Clinical Autonomic Research;2024-07-22

2. The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials;Journal of Diabetes and its Complications;2024-07

3. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project);JMIR Research Protocols;2024-05-29

4. Is GFR decline induced by SGLT2 inhibitor of clinical importance?;Cardiovascular Diabetology;2024-05-29

5. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project) (Preprint);2024-01-04